<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01496638</url>
  </required_header>
  <id_info>
    <org_study_id>20080192</org_study_id>
    <nct_id>NCT01496638</nct_id>
  </id_info>
  <brief_title>The Nordic-Baltic Bifurcation Study IV</brief_title>
  <acronym>BIF IV</acronym>
  <official_title>How Should Coronary Artery Stenoses With Significant Side Branch be Stented? A Strategy of Stenting Both Main Vessel and Side Branch Compared to a Strategy of Stenting the Main Vessel and Only Stenting the Side Branch if Necessary.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Niels Ramsing Holm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johnson &amp; Johnson</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aarhus University Hospital Skejby</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      How should coronary artery stenoses with significant side branch be stented?&#xD;
&#xD;
      A strategy of stenting both main vessel and side branch compared to a strategy of stenting&#xD;
      the main vessel and only stenting the side branch if necessary.&#xD;
&#xD;
      The 2-stent strategy is superior to the 1-stent strategy regarding occurrence of cardiac&#xD;
      death, non-procedure related myocardial infarction and re-revascularization with percutaneous&#xD;
      coronary intervention (PCI) or coronary artery bypass grafting (CABG).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design:&#xD;
&#xD;
        -  Randomised open multicentre trial.&#xD;
&#xD;
      Patients:&#xD;
&#xD;
        -  Number 450.&#xD;
&#xD;
      Randomisation:&#xD;
&#xD;
        -  No side branch treatment group or stenting of main vessel and side branch group.&#xD;
&#xD;
      Evaluation of endpoints:&#xD;
&#xD;
        -  Primary and secondary endpoints will be assessed by an independent endpoint committee.&#xD;
&#xD;
        -  The endpoint committee will consist of experienced cardiologists with professor Kristian&#xD;
           Thygesen, Aarhus Universitetshospital, as chairman.&#xD;
&#xD;
      Sample size calculation:&#xD;
&#xD;
        -  A total of 225 patients will be included in each group, in total 450 patients. We expect&#xD;
           a primary endpoint rate of 10% (cardiac death, non-procedure related myocardial&#xD;
           infarction related to index lesion or TLR after 6 months) in the 1- stent strategy group&#xD;
           and of 3% in the 2-stent strategy group. With an alpha of 5% and a strength of 80%, 194&#xD;
           patients will be needed in each group (two-sided chi-square test) to demonstrate this&#xD;
           difference. The expected primary endpoint rate after 6 months is based on 6 months MACE&#xD;
           rates and on the angiographic results in our previously published studies. In these&#xD;
           studies, a 6 months MACE rate of 3.7% was found in the culotte group of the Nordic Stent&#xD;
           Technique Study. Besides, an angiographic restenosis rate of 19.2% in the 1-stent&#xD;
           strategy group in the Nordic Bifurcation Study is estimated to translate to a MACE rate&#xD;
           of approximately 10% in the present study.&#xD;
&#xD;
      Analysis of the population:&#xD;
&#xD;
        -  The results will be analyzed according to the intention-to-treat principle.&#xD;
&#xD;
      Data management:&#xD;
&#xD;
        -  The study is reported to Datatilsynet (The Danish Data Protection Agency) and the&#xD;
           agency's guidelines for data management will be followed.&#xD;
&#xD;
      Dedicated case record forms (CRF) will be used and faxed to PCI research, Cardiac Cath. Lab.,&#xD;
      Aarhus University Hospital, Skejby, DK-8200 Aarhus N, Denmark. Data will be stored in an&#xD;
      Access database and double data entry will be used as quality control. There will be a log of&#xD;
      accesses and attempt of accesses. Back-up data and original data will be cryptotized.&#xD;
&#xD;
      Monitoring of the study:&#xD;
&#xD;
        -  The study will be monitored according to the GCP rules by independent professionals.&#xD;
           During the study period, monitors will have regular contact to the participating&#xD;
           departments to ensure that the trial is conducted in compliance with the protocol, GCP&#xD;
           and applicable regulatory requirements&#xD;
&#xD;
      Publication:&#xD;
&#xD;
        -  Results, positive as well as negative, will be published in an international&#xD;
           cardiovascular journal. Publication and author issues will be decided by the steering&#xD;
           committee on basis of general involvement in the study (drafting of protocol, core lab.&#xD;
           function, end point committee membership, etc.) and of number of included patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2008</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined endpoint of: Cardiac death, non-index procedure related myocardial infarction or target lesion revascularisation</measure>
    <time_frame>After 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE (cardiac death, non-index procedure related myocardial infarction, stent thrombosis or target lesion revasculation)</measure>
    <time_frame>During admission, after 1, 24, 36 and 60 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death.</measure>
    <time_frame>During the admission, after 1, 6, 24, 36 and 60 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-index procedure related myocardial infarction during the admission.</measure>
    <time_frame>After 1, 6, 24, 36 and 60 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis.</measure>
    <time_frame>During admission, after 1, 6, 24, 36 and 60 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total mortality</measure>
    <time_frame>During admission, after 1, 6, 24, 36 and 60 months and 10 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target lesion revascularisation.</measure>
    <time_frame>During admission, after 1, 6, 24, 36 and 60 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target vessel revascularisation.</measure>
    <time_frame>During admission, after 1, 6, 24, 36 and 60 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Index procedure related myocardial infarction based on biomarkers (CK-MB mass, TNT/TNI</measure>
    <time_frame>During hospital period, 1, 8, 24, 36 and 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CCS angina class</measure>
    <time_frame>After 6, 8, 24, 36 and 60 months.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">450</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>&quot;No side branch treatment&quot; group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of coronary stent in bifurcation lesion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;Stenting of main vessel and side branch&quot; group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of coronary stent in bifurcation lesion</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Implantation of coronary stent in bifurcation lesion</intervention_name>
    <description>Implantation of coronary stent in bifurcation lesion with no side branch treatment</description>
    <arm_group_label>&quot;No side branch treatment&quot; group</arm_group_label>
    <other_name>PCI</other_name>
    <other_name>PTCA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Implantation of coronary stent in bifurcation lesion</intervention_name>
    <description>Implantation of coronary stent in bifurcation lesion with stenting of main vessel and side branch</description>
    <arm_group_label>&quot;Stenting of main vessel and side branch&quot; group</arm_group_label>
    <other_name>PCI</other_name>
    <other_name>PTCA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stable or unstable angina pectoris or silent angina pectoris.&#xD;
&#xD;
          -  Genuine bifurcation lesion ( Medina type 1,1,1 or 1,0,1 or 0,1,1)&#xD;
&#xD;
          -  Lesion of &quot;LAD/diagonal&quot;, &quot;Cx/obtuse marginal&quot;, &quot;RCA-PDA/posterolateral branch&quot; or&#xD;
             &quot;LM/Cx/LAD&quot;.&#xD;
&#xD;
          -  Diameter of main vessel by visual estimate &gt;3.0 mm.&#xD;
&#xD;
          -  Diameter of side branch by visual estimate &gt;2.75 mm.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ST-elevation infarction within 24 hours.&#xD;
&#xD;
          -  Side branch lesion length &gt;15 mm.&#xD;
&#xD;
          -  Expected survival &lt; 1 year.&#xD;
&#xD;
          -  S-creatinine &gt;200 µmol/l.&#xD;
&#xD;
          -  Allergy to Aspirin, Clopidogrel or Ticlopidine.&#xD;
&#xD;
          -  Allergy to Sirolimus.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niels R Holm, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Skejby</city>
        <state>Aarhus N</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 19, 2011</study_first_submitted>
  <study_first_submitted_qc>December 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2011</study_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital Skejby</investigator_affiliation>
    <investigator_full_name>Niels Ramsing Holm</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>PCI</keyword>
  <keyword>Bifurcation lesion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

